Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.64 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.64 |
| ▸ | MC3R | P41968 | 13/20 | 0.55 |
| ▸ | MC4R | P32245 | 13/20 | 0.55 |
| ▸ | MC5R | P33032 | 12/20 | 0.55 |
| ▸ | MC1R | Q01726 | 10/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.50 |
| ▸ | ITGAV | P06756 | 1/20 | 0.50 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.50 |
| ▸ | TACR2 | P21452 | 1/20 | 0.49 |
| ▸ | KRAS | P01116 | 1/20 | 0.48 |
| ▸ | KDM4A | O75164 | 1/20 | 0.47 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19831554 | 0.98 | OPRM1 (0.61) | OPRM1OPRD1MC3RMC4RMC5R | |
| SCHEMBL23317973 | 0.97 | OPRM1 (0.58) | OPRM1OPRD1MC3RMC4RMC5R | |
| SCHEMBL13478156 | 0.88 | OPRM1 (0.61) | OPRM1OPRD1MC3RMC4RMC5R | |
| SCHEMBL12706706 | 0.88 | OPRM1 (0.61) | OPRM1OPRD1MC3RMC4RMC5R | |
| SCHEMBL13739916 | 0.88 | OPRM1 (0.61) | OPRM1OPRD1MC3RMC4RMC5R | |
| SCHEMBL29924992 | 0.86 | MC4R (0.58) | MC3RMC4RMC5RMC1RTACR2 | |
| SCHEMBL29924705 | 0.85 | MC4R (0.57) | MC3RMC4RMC5RMC1RTACR2 | |
| SCHEMBL30169340 | 0.84 | HDAC3 (0.59) | OPRM1OPRD1MC3RMC4RMC5R | |
| SCHEMBL29664052 | 0.82 | MC3R (0.80) | OPRM1OPRD1MC3RMC4RMC5R | |
| SCHEMBL13121283 | 0.82 | MEN1 (0.56) | MC3RMC4RMC5RMC1RKLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210130409-A1 | Method for the Solid-Phase Synthesis of Cyclic Pentapeptides | Alsonex Pty Ltd (AU) | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130409-A1 | Method for the Solid-Phase Synthesis of Cyclic Pentapeptides | ARG1, PNISR, HRH3 | OPRM1 715/4885OPRD1 701/4885MC3R 489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.